Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells

Colloids and Surfaces B: Biointerfaces

Volumn 85, Issue 2, 2011, Pages 131-137

  Kuo, Yung Chih ^a   Liang, Cheng Te ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Catanionic solid lipid nanoparticles; Doxorubicin; Epithelial growth factor receptor; Targeting; U87MG cell

Indexed keywords

DOXORUBICIN; EPITHELIAL GROWTH FACTOR RECEPTOR; SOLID LIPID NANOPARTICLES; TARGETING; U87MG CELL;

ANIONIC SURFACTANTS; BROMINE COMPOUNDS; NANOPARTICLES; PEPTIDES; SODIUM;

ENDOTHELIAL CELLS;

ANTINEOPLASTIC AGENT; CATIONIC SOLID LIPID NANOPARTICLE; DOXORUBICIN; DOXORUBICIN EPITHELIAL GROWTH RECEPTOR ANTIBODY; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES; BRAIN NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

THEOBROMA CACAO;

EID: 79955646431     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2011.02.011     Document Type: Article

References (43)

1. Tondre C., Caillet C. Properties of the amphiphilic films in mixed cationic/anionic vesicles: a comprehensive view from a literature analysis. Adv. Colloid Interface Sci. 2001, 93:115-134.
2. Dew N., Bramer T., Edsman K. Catanionic aggregates formed from drugs and lauric or capric acids enable prolonged release from gels. J. Colloid Interface Sci. 2008, 323:386-394.
3. Li X., Kunieda H. Catanionic surfactants: microemulsion formation and solubilization. Curr. Opin. Colloid Interface Sci. 2003, 8:327-336.
4. Wang Y., Bai G., Marques E.F., Yan H. Phase behavior and thermodynamics of a mixture of cationic gemini and anionic surfactant. J. Phys. Chem. B 2006, 110:5294-5300.
5. Shioi A., Hatton T.A. Model for formation and growth of vesicles in mixed anionic/cationic (SOS/CTAB) surfactant systems. Langmuir 2002, 18:7341-7348.
6. Yin H., Lin Y., Huang J. Microstructures and rheological dynamics of viscoelastic solutions in a catanionic surfactant system. J. Colloid Interface Sci. 2009, 338:177-183.
7. Speth P.J.A., Van Hoesel Q.G.C.M., Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 1998, 15:15-31.
8. Brigger I., Morizet J., Laudani L., Aubert G., Appel M., Velasco V., Terrier-Lacombe M.J., Desmaele D., d'Angelo J., Couvreur P., Vassal G. Negative preclinical results with stealth nanospheres - encapsulated doxorubicin in an orthotopic murine brain tumor model. J. Control. Release 2004, 100:29-40.
9. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57:679-686.
10. Hu F.Q., Liu L.N., Du Y.Z., Yuan H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 2009, 30:6955-6963.
11. Laginha K.M., Verwoert S., Charrois G.J., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 2005, 11:6944-6949.
12. Kang K.W., Chun M.K., Kim O., Subedi R.K., Ahn S.G., Yoon J.H., Choi S.G. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010, 6:210-213.
13. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
14. Serpe L., Catalano M.G., Cavalli R., Ugazio E., Bosco O., Canaparo R., Muntoni E., Frairia R., Gasco M.R., Eandi M., Zara G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 2004, 58:673-680.
15. Hershman D.L., McBride R.B., Eisenberger A., Tsai W.Y., Grann V.R., Jacobson J.S. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2008, 26:3159-3165.
16. Kuo Y.C., Yeh C.F., Yang J.T. Differentiation of bone marrow stromal cells in poly(lactide-co-glycolide)/chitosan scaffolds. Biomaterials 2009, 30:6604-6613.
17. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 2005, 290:161-172.
18. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 2009, 365:206-213.
19. Kuo Y.C., Lin C.W. Effect of electromagnetic field and surface modification on the electrical behavior of novel solid lipid nanoparticles covered with l-arginine. Colloids Surfaces B 2009, 71:45-51.
20. Maiti K., Bhattacharya S.C., Moulik S.P., Panda A.K. Physicochemistry of the binary interacting mixtures of cetylpyridinium chloride (CPC) and sodium dodecylsulfate (SDS) with special reference to the catanionic ion-pair (coacervate) behavior. Colloids Surfaces A 2010, 355:88-98.
21. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 2007, 340:143-152.
22. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 2008, 351:271-281.
23. Souto E.B., Anselmi C., Centini M., Müller R.H. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles. Int. J. Pharm. 2005, 295:261-268.
24. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 2006, 327:160-169.
25. Y.C. Kuo, P.I. Lin, C.C. Wang, Targeting nevirapine delivery across human brain microvesscular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles, Nanomedicine, accepted.
26. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surfaces B 2011, 83:299-306.
27. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J. Drug Target. 2010, 18:447-456.
28. Kuo Y.C., Wang C.C. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surfaces B 2010, 76:286-291.
29. Kuo Y.C., Lin T.W. Electrophoretic mobility, zeta potential, and fixed charge density of bovine knee chondrocytes, methylmethacrylate-sulfopropylmethacrylate, polybutylcyanoacrylate, and solid lipid nanoparticles. J. Phys. Chem. B 2006, 110:2202-2208.
30. Kuo Y.C., Lin S.C. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J. Phys. Chem. B 2008, 112:4454-4460.
31. Kuo Y.C., Chiu K.H. Inverted colloidal crystal scaffolds with laminin-derived peptides for neuronal differentiation of bone marrow stromal cells. Biomaterials 2011, 32:819-831.
32. Vlachy N., Touraud D., Heilmann J., Kunz W. Determining the cytotoxicity of catanionic surfactant mixtures on HeLa cells. Colloids Surfaces B 2009, 70:278-280.
33. Schöler N., Hahn H., Müller R.H., Liesenfeid O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002, 231:167-176.
34. Kuo Y.C., Shih K.H., Yang J.T. Capillary electrophoresis of bone marrow stromal cells with the uptake of heparin-functionalized poly(lactide-co-glycolide) nanoparticles during differentiation towards neurons. Electrophoresis 2010, 31:315-323.
35. Azarmi S., Tao X., Chen H., Wang Z., Finlay W.H., Löbenberg R., Roa W.H. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm. 2006, 319:155-161.
36. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 2000, 210:61-67.
37. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., Xi Y., Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226-232.
38. Zhang X.G., Miao J., Dai Y.Q., Du Y.Z., Yuan H., Hu F.Q. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm. 2008, 361:239-244.
39. Argyriou A.A., Antonacopoulou A., Iconomou G., Kalofonos H.P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit. Rev. Oncol. Hematol. 2009, 69:199-210.
40. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
41. Ortiz C., Caja L., Sancho P., Bertran E., Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem. Pharmacol. 2008, 75:1935-1945.
42. Duex J.E., Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Mol. Biol. Cell 2009, 20:1833-1844.
43. Zhan Y., Counelis G.J., O'Rourke D.M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp. Cell Res. 2009, 315:2343-2357.